person · Reporting owner

MUIR GLENN P

Disclosed activity across 5 companies

Tapewire entity: 21255
SEC CIK: 0001181190

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Cytek Biosciences, Inc.CTKB · Entity 5345	Director	August 18, 2026	August 20, 2026
Lifeward Ltd.RWLK · Entity 7620	Director	June 27, 2017	June 29, 2017
Neuronetics, Inc.STIM · Entity 6248	Director	May 28, 2026	May 29, 2026
REPLIGEN CORPRGEN · Entity 486	Director	May 14, 2026	May 18, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Cytek Biosciences, Inc.

Report date August 18, 2026 · Filed August 20, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	3,086	Reported balance After 2026-08-18 transaction · row 1 1 source row Row 1 · 2026-08-18 · Exercise / conversion · Acquired 3,086 · Balance 3,086 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	52,469	Reported balance After 2026-08-18 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-08-18 · Exercise / conversion · Disposed 3,086 · Balance 52,469 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F2: The shares underlying the RSU Award shall vest over 3 years, with 2/36 of the total shares underlying the RSU Award vesting on August 18, 2026; 3/36 of the total shares underlying the RSU Award vesting on November 18, 2026 and each November 18 thereafter; 4/36 of the total shares underlying the RSU Award vesting on March 10, 2027 and each March 10 thereafter; 3/36 of the total shares underlying the RSU Award vesting on May 18, 2027 and each May 18 thereafter; and 3/36 of the total shares underlying the RSU Award vesting on August 18, 2027 and each August 18 thereafter.

Filing footnotes · ownership attribution and instrument terms

F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.

F2: The shares underlying the RSU Award shall vest over 3 years, with 2/36 of the total shares underlying the RSU Award vesting on August 18, 2026; 3/36 of the total shares underlying the RSU Award vesting on November 18, 2026 and each November 18 thereafter; 4/36 of the total shares underlying the RSU Award vesting on March 10, 2027 and each March 10 thereafter; 3/36 of the total shares underlying the RSU Award vesting on May 18, 2027 and each May 18 thereafter; and 3/36 of the total shares underlying the RSU Award vesting on August 18, 2027 and each August 18 thereafter.

Lifeward Ltd.

Report date June 27, 2017 · Filed June 29, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.10 · Expires 2027-06-27	Direct	4,176	Reported balance After 2017-06-27 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2017-06-27 · Grant · Acquired 4,176 · Balance 4,176 F1: Represents stock options granted under the ReWalk 2014 Equity Incentive Plan on June 27, 2017. The options become vested and exercisable in four equal quarterly installments starting three months following the date of grant.

Filing footnotes · ownership attribution and instrument terms

F1: Represents stock options granted under the ReWalk 2014 Equity Incentive Plan on June 27, 2017. The options become vested and exercisable in four equal quarterly installments starting three months following the date of grant.

Neuronetics, Inc.

Report date May 28, 2026 · Filed May 29, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	401,816	Reported balance After 2026-05-28 transaction · row 1 1 source row Row 1 · 2026-05-28 · Grant · Acquired 30,000 · Balance 401,816 F1: Represents a restricted stock unit ("RSU") award that vests on the earlier of (a) May 28, 2027 or (b) the Reporting Person's Board-approved separation of service from the Issuer or change in control of the Issuer, in each case subject to continuous service of the Reporting Person through such date. F2: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

Filing footnotes · ownership attribution and instrument terms

F1: Represents a restricted stock unit ("RSU") award that vests on the earlier of (a) May 28, 2027 or (b) the Reporting Person's Board-approved separation of service from the Issuer or change in control of the Issuer, in each case subject to continuous service of the Reporting Person through such date.

F2: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

REPLIGEN CORP

Report date May 14, 2026 · Filed May 18, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	40,051	Reported balance After 2026-05-14 transaction · row 1 1 source row Row 1 · 2026-05-14 · Grant · Acquired 995 · Balance 40,051 F1: Mr. Muir was awarded 995 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 14, 2027, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The Reporting Person has elected to defer settlement of these restricted stock units pursuant to the Repligen Corporation Deferred Compensation Plan for Non-Employee Directors. Once vested, the shares will be issued in accordance with the Reporting Person's deferral election following the separation of the Reporting Person's service as a Director. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $103.38 · Expires 2036-05-14	Direct	2,239	Reported balance After 2026-05-14 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-05-14 · Grant · Acquired 2,239 · Balance 2,239 F2: Award vests in full on the earlier of May 14, 2027, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined.

Filing footnotes · ownership attribution and instrument terms

F1: Mr. Muir was awarded 995 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 14, 2027, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The Reporting Person has elected to defer settlement of these restricted stock units pursuant to the Repligen Corporation Deferred Compensation Plan for Non-Employee Directors. Once vested, the shares will be issued in accordance with the Reporting Person's deferral election following the separation of the Reporting Person's service as a Director. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.

F2: Award vests in full on the earlier of May 14, 2027, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

G1 Therapeutics, Inc.

Report date September 18, 2024 · Filed September 18, 2024

Section 16 reporting ended · disclosed 2024-09-18. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Ending reported balance After 2024-09-18 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2024-09-18 · Disposition to issuer · Disposed 20,000 · Balance 185,358 F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 6, 2024, among the Issuer, Pharmacosmos A/S, a Danish Aktieselskab ("Parent"), and Genesis Merger Sub, Inc. ("Purchaser"), an indirect wholly-owned subsidiary of Parent, Purchaser completed a tender offer for shares of common stock of the Issuer and thereafter merged with and into the Issuer (the "Merger"), effective as of September 18, 2024, with the Issuer surviving the Merger. At the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled and converted into the right to receive $7.15 per share in cash, without interest and subject to any applicable withholding taxes (the "Merger Consideration"). F2: (Continued from footnote 1) Pursuant to the Merger Agreement, at the Effective Time, each outstanding deferred stock unit (whether vested or unvested) was deemed to have vested and was cancelled and automatically converted into the right to receive an amount in cash equal to the Merger Consideration. Row 2 · 2024-09-18 · Other · Disposed 185,358 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each share of common stock held by the Reporting Person was tendered in exchange for the Merger Consideration.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.99 · Expires 2034-06-13	Direct	Reported balance After 2024-09-18 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2024-09-18 · Disposition to issuer · Disposed 30,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each "Stock Option") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.83 · Expires 2033-06-15	Direct	Reported balance After 2024-09-18 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2024-09-18 · Disposition to issuer · Disposed 30,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each "Stock Option") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.30 · Expires 2032-06-23	Direct	Reported balance After 2024-09-18 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2024-09-18 · Disposition to issuer · Disposed 30,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each "Stock Option") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.30 · Expires 2025-09-07	Direct	Reported balance After 2024-09-18 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2024-09-18 · Disposition to issuer · Disposed 50,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each "Stock Option") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 6, 2024, among the Issuer, Pharmacosmos A/S, a Danish Aktieselskab ("Parent"), and Genesis Merger Sub, Inc. ("Purchaser"), an indirect wholly-owned subsidiary of Parent, Purchaser completed a tender offer for shares of common stock of the Issuer and thereafter merged with and into the Issuer (the "Merger"), effective as of September 18, 2024, with the Issuer surviving the Merger. At the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled and converted into the right to receive $7.15 per share in cash, without interest and subject to any applicable withholding taxes (the "Merger Consideration").

F2: (Continued from footnote 1) Pursuant to the Merger Agreement, at the Effective Time, each outstanding deferred stock unit (whether vested or unvested) was deemed to have vested and was cancelled and automatically converted into the right to receive an amount in cash equal to the Merger Consideration.

F3: Pursuant to the Merger Agreement, at the Effective Time, each share of common stock held by the Reporting Person was tendered in exchange for the Merger Consideration.

F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each "Stock Option") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
August 18, 2026 Filed Aug 20, 2026 20:31 UTC	Cytek Biosciences, Inc. CTKB · Entity 5345	Exercise / conversionRestricted Stock Units · Derivative	3,086	$0.00	$0.00	Disclosure SEC source: 0001181190-26-000007 · form4-08202026_080825.xml · derivative · entry 2 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,469 Underlying: Common Stock · 3,086 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The shares underlying the RSU Award shall vest over 3 years, with 2/36 of the total shares underlying the RSU Award vesting on August 18, 2026; 3/36 of the total shares underlying the RSU Award vesting on November 18, 2026 and each November 18 thereafter; 4/36 of the total shares underlying the RSU Award vesting on March 10, 2027 and each March 10 thereafter; 3/36 of the total shares underlying the RSU Award vesting on May 18, 2027 and each May 18 thereafter; and 3/36 of the total shares underlying the RSU Award vesting on August 18, 2027 and each August 18 thereafter. F2 · derivative.expiration_date: The shares underlying the RSU Award shall vest over 3 years, with 2/36 of the total shares underlying the RSU Award vesting on August 18, 2026; 3/36 of the total shares underlying the RSU Award vesting on November 18, 2026 and each November 18 thereafter; 4/36 of the total shares underlying the RSU Award vesting on March 10, 2027 and each March 10 thereafter; 3/36 of the total shares underlying the RSU Award vesting on May 18, 2027 and each May 18 thereafter; and 3/36 of the total shares underlying the RSU Award vesting on August 18, 2027 and each August 18 thereafter. Read SEC document
August 18, 2026 Filed Aug 20, 2026 20:31 UTC	Cytek Biosciences, Inc. CTKB · Entity 5345	Exercise / conversionCommon Stock	3,086	Not disclosed	Not disclosed	Disclosure SEC source: 0001181190-26-000007 · form4-08202026_080825.xml · nonDerivative · entry 1 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,086 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document
June 10, 2026 Filed Jun 12, 2026 23:31 UTC	Cytek Biosciences, Inc. CTKB · Entity 5345	GrantDirector Stock Option (right to buy) · Derivative	29,835	$0.00 Strike: $4.05	$0.00	Disclosure SEC source: 0001181190-26-000005 · form4-06122026_110625.xml · derivative · entry 2 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,835 Underlying: Common Stock · 29,835 shares Expires 2036-06-10 F3 · derivative.exercise_date: 1/36 of the total shares subject to the option shall vest monthly over 3 years following the grant date of June 10, 2026. Read SEC document
June 10, 2026 Filed Jun 12, 2026 23:31 UTC	Cytek Biosciences, Inc. CTKB · Entity 5345	GrantRestricted Stock Units · Derivative	55,555	$0.00	$0.00	Disclosure SEC source: 0001181190-26-000005 · form4-06122026_110625.xml · derivative · entry 1 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,555 Underlying: Common Stock · 55,555 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: 2/36 of the total shares subject to the RSU Award shall vest on August 18, 2026; 3/36 of the total shares subject to the RSU Award shall vest on November 18, 2026 and each November 18 thereafter; 4/36 of the total shares underlying the RSU Award shall vest on March 10, 2027 and each March 10 thereafter; 3/36 of the total shares underlying the RSU Award vesting shall vest on May 18, 2027 and each May 18 thereafter; and 3/36 of the total shares underlying the RSU Award shall vest on August 18, 2027 and each August 18 thereafter, until fully vested. F2 · derivative.expiration_date: 2/36 of the total shares subject to the RSU Award shall vest on August 18, 2026; 3/36 of the total shares subject to the RSU Award shall vest on November 18, 2026 and each November 18 thereafter; 4/36 of the total shares underlying the RSU Award shall vest on March 10, 2027 and each March 10 thereafter; 3/36 of the total shares underlying the RSU Award vesting shall vest on May 18, 2027 and each May 18 thereafter; and 3/36 of the total shares underlying the RSU Award shall vest on August 18, 2027 and each August 18 thereafter, until fully vested. Read SEC document
May 28, 2026 Filed May 29, 2026 21:05 UTC	Neuronetics, Inc. STIM · Entity 6248	GrantCommon Stock	30,000	$0.00	$0.00	Disclosure SEC source: 0001181190-26-000002 · ownership.xml · nonDerivative · entry 1 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 401,816 F1 · shares: Represents a restricted stock unit ("RSU") award that vests on the earlier of (a) May 28, 2027 or (b) the Reporting Person's Board-approved separation of service from the Issuer or change in control of the Issuer, in each case subject to continuous service of the Reporting Person through such date. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document
May 14, 2026 Filed May 18, 2026 20:05 UTC	REPLIGEN CORP RGEN · Entity 486	GrantStock Option (Right to Buy) · Derivative	2,239	$0.00 Strike: $103.38	$0.00	Disclosure SEC source: 0001193125-26-228891 · ownership.xml · derivative · entry 2 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,239 Underlying: Common Stock · 2,239 shares Expires 2036-05-14 F2 · derivative.exercise_date: Award vests in full on the earlier of May 14, 2027, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined. Read SEC document
May 14, 2026 Filed May 18, 2026 20:05 UTC	REPLIGEN CORP RGEN · Entity 486	GrantCommon Stock	995	$0.00	$0.00	Disclosure SEC source: 0001193125-26-228891 · ownership.xml · nonDerivative · entry 1 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,051 F1 · shares: Mr. Muir was awarded 995 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 14, 2027, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The Reporting Person has elected to defer settlement of these restricted stock units pursuant to the Repligen Corporation Deferred Compensation Plan for Non-Employee Directors. Once vested, the shares will be issued in accordance with the Reporting Person's deferral election following the separation of the Reporting Person's service as a Director. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document
May 07, 2026 Filed May 8, 2026 18:48 UTC	REPLIGEN CORP RGEN · Entity 486	Exercise / conversionStock Option (Right to Buy) · Derivative	2,434	$0.00 Strike: $38.76	$0.00	Disclosure SEC source: 0001193125-26-214293 · ownership.xml · derivative · entry 2 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,434 Underlying: Common Stock · 2,434 shares Expires 2027-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document
May 07, 2026 Filed May 8, 2026 18:48 UTC	REPLIGEN CORP RGEN · Entity 486	Exercise / conversionCommon Stock	2,434	$38.76	$94,341.84	Disclosure SEC source: 0001193125-26-214293 · ownership.xml · nonDerivative · entry 1 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,056 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 16, 2025 Filed Dec 17, 2025 21:30 UTC	REPLIGEN CORP RGEN · Entity 486	Exercise / conversionStock Option (Right to Buy) · Derivative	3,366	$0.00 Strike: $26.12	$0.00	Disclosure SEC source: 0001193125-25-322821 · ownership.xml · derivative · entry 2 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,366 Underlying: Common Stock · 3,366 shares Expires 2026-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document
December 16, 2025 Filed Dec 17, 2025 21:30 UTC	REPLIGEN CORP RGEN · Entity 486	Exercise / conversionCommon Stock	3,366	$26.12	$87,919.92	Disclosure SEC source: 0001193125-25-322821 · ownership.xml · nonDerivative · entry 1 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,622 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
October 20, 2025 Filed Oct 22, 2025 20:45 UTC	Neuronetics, Inc. STIM · Entity 6248	GrantCommon Stock	7,554	$0.00	$0.00	Disclosure SEC source: 0001193125-25-246921 · ownership.xml · nonDerivative · entry 1 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 371,816 F1 · kind: Pursuant to the Issuer's non-employee directors compensation plan the Reporting Person elected to receive shares of the Issuer's Common Stock in lieu of a cash retainer. F2 · shares: Represents a restricted stock unit ("RSU") award that vested immediately upon the grant. F3 · price: Each RSU represents a right to receive one share of the Issuer's common stock. Read SEC document
May 22, 2025 Filed May 27, 2025 21:00 UTC	Neuronetics, Inc. STIM · Entity 6248	GrantCommon Stock	30,000	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-25-077824 · ownership.xml · nonDerivative · entry 1 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 364,262 F1 · shares: Represents a restricted stock unit ("RSU") award that vests on the earlier of (a) May 22, 2026 or (b) the Reporting Person's Board-approved separation of service from the Issuer, in each case subject to continuous service of the Reporting Person through such date. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document
May 15, 2025 Filed May 20, 2025 00:19 UTC	REPLIGEN CORP RGEN · Entity 486	GrantStock Option (Right to Buy) · Derivative	1,800	$0.00 Strike: $123.26	$0.00	Disclosure SEC source: 0000950170-25-074752 · ownership.xml · derivative · entry 2 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,800 Underlying: Common Stock · 1,800 shares Expires 2035-05-15 F2 · derivative.exercise_date: Award vests in full on the earlier of May 15, 2026, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined. Read SEC document
May 15, 2025 Filed May 20, 2025 00:19 UTC	REPLIGEN CORP RGEN · Entity 486	GrantCommon Stock	973	$0.00	$0.00	Disclosure SEC source: 0000950170-25-074752 · ownership.xml · nonDerivative · entry 1 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,256 F1 · shares: Mr. Muir was awarded 973 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 15, 2026, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document
February 07, 2025 Filed Feb 10, 2025 22:18 UTC	Neuronetics, Inc. STIM · Entity 6248	OtherCommon Stock	44,444	$2.25	$99,999.00	Disclosure SEC source: 0000950170-25-017195 · ownership.xml · nonDerivative · entry 1 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 334,262 F1 · kind: On February 7, 2025, the Reporting Person purchased 44,444 shares of the Issuer's Common Stock in connection with a firm commitment underwritten offering. Read SEC document
November 19, 2024 Filed Nov 20, 2024 19:29 UTC	REPLIGEN CORP RGEN · Entity 486	Exercise / conversionStock Option (Right to Buy) · Derivative	19,000	$0.00 Strike: $36.29	$0.00	Disclosure SEC source: 0000950170-24-129145 · ownership.xml · derivative · entry 2 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,000 shares Expires 2025-09-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document
November 19, 2024 Filed Nov 20, 2024 19:29 UTC	REPLIGEN CORP RGEN · Entity 486	Exercise / conversionCommon Stock	19,000	$36.29	$689,510.00	Disclosure SEC source: 0000950170-24-129145 · ownership.xml · nonDerivative · entry 1 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,283 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
September 18, 2024 Filed Sep 18, 2024 20:15 UTC	G1 Therapeutics, Inc. GTHX · Entity 87413	Disposition to issuerStock Option (right to buy) · Derivative	50,000	Not disclosed Strike: $0.30	Not disclosed	Disclosure SEC source: 0000950170-24-107788 · ownership.xml · derivative · entry 6 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2025-09-07 F4 · kind: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each "Stock Option") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option. F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each "Stock Option") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each "Stock Option") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option. Read SEC document
September 18, 2024 Filed Sep 18, 2024 20:15 UTC	G1 Therapeutics, Inc. GTHX · Entity 87413	Disposition to issuerStock Option (right to buy) · Derivative	30,000	Not disclosed Strike: $5.30	Not disclosed	Disclosure SEC source: 0000950170-24-107788 · ownership.xml · derivative · entry 5 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2032-06-23 F4 · kind: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each "Stock Option") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option. F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each "Stock Option") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each "Stock Option") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option. Read SEC document
September 18, 2024 Filed Sep 18, 2024 20:15 UTC	G1 Therapeutics, Inc. GTHX · Entity 87413	Disposition to issuerStock Option (right to buy) · Derivative	30,000	Not disclosed Strike: $2.83	Not disclosed	Disclosure SEC source: 0000950170-24-107788 · ownership.xml · derivative · entry 4 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2033-06-15 F4 · kind: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each "Stock Option") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option. F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each "Stock Option") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each "Stock Option") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option. Read SEC document
September 18, 2024 Filed Sep 18, 2024 20:15 UTC	G1 Therapeutics, Inc. GTHX · Entity 87413	Disposition to issuerStock Option (right to buy) · Derivative	30,000	Not disclosed Strike: $2.99	Not disclosed	Disclosure SEC source: 0000950170-24-107788 · ownership.xml · derivative · entry 3 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2034-06-13 F4 · kind: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each "Stock Option") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option. F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each "Stock Option") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each "Stock Option") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option. Read SEC document
September 18, 2024 Filed Sep 18, 2024 20:15 UTC	G1 Therapeutics, Inc. GTHX · Entity 87413	OtherCommon Stock	185,358	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-24-107788 · ownership.xml · nonDerivative · entry 2 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F3 · kind: Pursuant to the Merger Agreement, at the Effective Time, each share of common stock held by the Reporting Person was tendered in exchange for the Merger Consideration. F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each share of common stock held by the Reporting Person was tendered in exchange for the Merger Consideration. Read SEC document
September 18, 2024 Filed Sep 18, 2024 20:15 UTC	G1 Therapeutics, Inc. GTHX · Entity 87413	Disposition to issuerCommon Stock	20,000	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-24-107788 · ownership.xml · nonDerivative · entry 1 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 185,358 F1 · kind: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 6, 2024, among the Issuer, Pharmacosmos A/S, a Danish Aktieselskab ("Parent"), and Genesis Merger Sub, Inc. ("Purchaser"), an indirect wholly-owned subsidiary of Parent, Purchaser completed a tender offer for shares of common stock of the Issuer and thereafter merged with and into the Issuer (the "Merger"), effective as of September 18, 2024, with the Issuer surviving the Merger. At the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled and converted into the right to receive $7.15 per share in cash, without interest and subject to any applicable withholding taxes (the "Merger Consideration"). F2 · kind: (Continued from footnote 1) Pursuant to the Merger Agreement, at the Effective Time, each outstanding deferred stock unit (whether vested or unvested) was deemed to have vested and was cancelled and automatically converted into the right to receive an amount in cash equal to the Merger Consideration. F1 · price: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 6, 2024, among the Issuer, Pharmacosmos A/S, a Danish Aktieselskab ("Parent"), and Genesis Merger Sub, Inc. ("Purchaser"), an indirect wholly-owned subsidiary of Parent, Purchaser completed a tender offer for shares of common stock of the Issuer and thereafter merged with and into the Issuer (the "Merger"), effective as of September 18, 2024, with the Issuer surviving the Merger. At the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled and converted into the right to receive $7.15 per share in cash, without interest and subject to any applicable withholding taxes (the "Merger Consideration"). F2 · price: (Continued from footnote 1) Pursuant to the Merger Agreement, at the Effective Time, each outstanding deferred stock unit (whether vested or unvested) was deemed to have vested and was cancelled and automatically converted into the right to receive an amount in cash equal to the Merger Consideration. Read SEC document
September 05, 2024 Filed Sep 6, 2024 21:05 UTC	Neuronetics, Inc. STIM · Entity 6248	PurchaseCommon Stock	25,000	$0.80	$20,000.00	Disclosure SEC source: 0000950170-24-104427 · ownership.xml · nonDerivative · entry 1 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 289,818 Read SEC document
August 29, 2024 Filed Aug 30, 2024 21:15 UTC	Neuronetics, Inc. STIM · Entity 6248	PurchaseCommon Stock	12,224	$0.85	$10,390.40	Disclosure SEC source: 0000950170-24-102437 · ownership.xml · nonDerivative · entry 2 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 264,818 Read SEC document
August 28, 2024 Filed Aug 30, 2024 21:15 UTC	Neuronetics, Inc. STIM · Entity 6248	PurchaseCommon Stock	12,776	$0.85	$10,859.60	Disclosure SEC source: 0000950170-24-102437 · ownership.xml · nonDerivative · entry 1 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 252,594 Read SEC document
August 20, 2024 Filed Aug 21, 2024 21:15 UTC	Neuronetics, Inc. STIM · Entity 6248	PurchaseCommon Stock	25,000	$1.00	$25,000.00	Disclosure SEC source: 0000950170-24-099560 · ownership.xml · nonDerivative · entry 1 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 239,818 Read SEC document
August 14, 2024 Filed Aug 16, 2024 21:15 UTC	Neuronetics, Inc. STIM · Entity 6248	PurchaseCommon Stock	25,171	$0.75	$18,878.25	Disclosure SEC source: 0000950170-24-098142 · ownership.xml · nonDerivative · entry 1 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 214,818 Read SEC document
August 01, 2024 Filed Aug 1, 2024 21:04 UTC	REPLIGEN CORP RGEN · Entity 486	Exercise / conversionStock Option (Right to Buy) · Derivative	5,000	$0.00 Strike: $36.29	$0.00	Disclosure SEC source: 0000950170-24-089409 · ownership.xml · derivative · entry 2 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2025-09-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document
August 01, 2024 Filed Aug 1, 2024 21:04 UTC	REPLIGEN CORP RGEN · Entity 486	Exercise / conversionCommon Stock	5,000	$36.29	$181,450.00	Disclosure SEC source: 0000950170-24-089409 · ownership.xml · nonDerivative · entry 1 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,283 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 13, 2024 Filed Jun 14, 2024 20:41 UTC	G1 Therapeutics, Inc. GTHX · Entity 87413	GrantStock Options (Right to Buy) · Derivative	30,000	$0.00 Strike: $2.99	$0.00	Disclosure SEC source: 0001562180-24-005082 · primarydocument.xml · derivative · entry 2 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2034-06-13 F4 · derivative.exercise_date: The shares underlying this option will vest in their entirety twelve months after June 13, 2024, subject to the Reporting Person's continued service as a director. Read SEC document
June 13, 2024 Filed Jun 14, 2024 20:41 UTC	G1 Therapeutics, Inc. GTHX · Entity 87413	GrantCommon Stock	10,000	$0.00	$0.00	Disclosure SEC source: 0001562180-24-005082 · primarydocument.xml · nonDerivative · entry 1 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 205,358 F1 · shares: Represents a restricted stock unit ("RSU") award that vests in its entirety twelve months after June 13, 2024, subject to the Reporting Person's continued service as a director. The Reporting Person has elected to defer vesting of these shares pursuant to the G1 Therapeutics, Inc. Deferred Compensation Plan for Non-Employee Directors. The RSUs will vest upon termination of the Reporting Person's service as a Director on the Company's Board. F2 · price: Each RSU represents a contingent right to receive one share of Issuer common stock. F3 · balance_after: Represents (i) 185,358 shares of common stock; (ii) 10,000 RSUs from award granted on June 15, 2023; and (iii) 10,000 RSUs from award granted on June 13, 2024. Read SEC document
May 30, 2024 Filed Jun 6, 2024 00:14 UTC	Neuronetics, Inc. STIM · Entity 6248	GrantCommon Stock	25,000	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-24-069564 · ownership.xml · nonDerivative · entry 1 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 189,647 F1 · shares: Represents a restricted stock unit ("RSU") award that vests on the earlier of (a) May 30, 2025, or (b) the reporting person's Board-approved separation of service from the Issuer, in each case subject to continuous service of the reporting person through such date. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document
May 16, 2024 Filed May 20, 2024 22:49 UTC	REPLIGEN CORP RGEN · Entity 486	GrantStock Option (Right to Buy) · Derivative	1,376	$0.00 Strike: $171.03	$0.00	Disclosure SEC source: 0000950170-24-062597 · ownership.xml · derivative · entry 2 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,376 Underlying: Common Stock · 1,376 shares Expires 2034-05-16 F2 · derivative.exercise_date: Award vests in full on the earlier of May 16, 2025, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined. Read SEC document
May 16, 2024 Filed May 20, 2024 22:49 UTC	REPLIGEN CORP RGEN · Entity 486	GrantCommon Stock	701	$0.00	$0.00	Disclosure SEC source: 0000950170-24-062597 · ownership.xml · nonDerivative · entry 1 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,283 F1 · shares: Mr. Muir was awarded 701 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 16, 2025, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document
June 15, 2023 Filed Jun 16, 2023 20:07 UTC	G1 Therapeutics, Inc. GTHX · Entity 87413	GrantStock Options (Right to Buy) · Derivative	30,000	$0.00 Strike: $2.83	$0.00	Disclosure SEC source: 0001562180-23-005270 · primarydocument.xml · derivative · entry 2 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2033-06-15 F4 · derivative.exercise_date: The shares underlying this option will vest in their entirety twelve months after June 15, 2023, subject to the Reporting Person's continued service as a director. Read SEC document
June 15, 2023 Filed Jun 16, 2023 20:07 UTC	G1 Therapeutics, Inc. GTHX · Entity 87413	GrantCommon Stock	10,000	$0.00	$0.00	Disclosure SEC source: 0001562180-23-005270 · primarydocument.xml · nonDerivative · entry 1 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 195,358 F1 · shares: Represents a restricted stock unit ("RSU") award that vests in its entirety twelve months after June 15, 2023, subject to the Reporting Person's continued service as a director. The Reporting Person has elected to defer vesting of these shares pursuant to the G1 Therapeutics, Inc. Deferred Compensation Plan for Non-Employee Directors. The RSUs will vest upon termination of the Reporting Person's service as a Director on the Company's Board. F2 · price: Each RSU represents a contingent right to receive one share of Issuer common stock. F3 · balance_after: Represents (i) 175,358 shares of common stock; (ii) 10,000 RSUs from award granted on June 23, 2022; and (iii) 10,000 RSUs from award granted on June 15, 2023. Read SEC document
May 25, 2023 Filed May 31, 2023 01:05 UTC	Neuronetics, Inc. STIM · Entity 6248	GrantCommon Stock	36,364	Not disclosed	Not disclosed	Disclosure SEC source: 0001062993-23-012485 · form4.xml · nonDerivative · entry 1 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 164,647 F1 · shares: Represents a restricted stock unit ("RSU") award that vests on the earlier of (a) May 23, 2024, or (b) the reporting person's Board-approved separation of service from the Issuer, in each case subject to continuous service of the reporting person through such date. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F3 · balance_after: Reflects an adjustment to total holdings to include 12 RSUs inadvertently excluded in prior reports. Read SEC document
May 18, 2023 Filed May 23, 2023 01:21 UTC	REPLIGEN CORP RGEN · Entity 486	GrantStock Option (Right to Buy) · Derivative	1,487	$0.00 Strike: $156.63	$0.00	Disclosure SEC source: 0000899243-23-013667 · doc4.xml · derivative · entry 2 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,487 Underlying: Common Stock · 1,487 shares Expires 2033-05-18 F2 · derivative.exercise_date: Award vests in full on the earlier of May 18, 2024, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined. Read SEC document
May 18, 2023 Filed May 23, 2023 01:21 UTC	REPLIGEN CORP RGEN · Entity 486	GrantCommon Stock	686	$0.00	$0.00	Disclosure SEC source: 0000899243-23-013667 · doc4.xml · nonDerivative · entry 1 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,582 F1 · shares: Mr. Muir was awarded 686 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 18, 2024, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document
June 23, 2022 Filed Jun 24, 2022 20:51 UTC	G1 Therapeutics, Inc. GTHX · Entity 87413	GrantStock Options (Right to Buy) · Derivative	30,000	$0.00 Strike: $5.30	$0.00	Disclosure SEC source: 0001562180-22-005350 · primarydocument.xml · derivative · entry 2 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2032-06-23 F4 · derivative.exercise_date: The shares underlying this option will vest in their entirety twelve months after June 23, 2022, subject to the Reporting Person's continued service as a director. Read SEC document
June 23, 2022 Filed Jun 24, 2022 20:51 UTC	G1 Therapeutics, Inc. GTHX · Entity 87413	GrantCommon Stock	10,000	$0.00	$0.00	Disclosure SEC source: 0001562180-22-005350 · primarydocument.xml · nonDerivative · entry 1 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,358 F1 · shares: Represents a restricted stock unit ("RSU") award that vests in its entirety twelve months after June 23, 2022, subject to the Reporting Person's continued service as a director. F2 · price: Each RSU represents a contingent right to receive one share of Issuer common stock F3 · balance_after: Represents 175,358 shares of common stock and 10,000 restricted stock units Read SEC document
May 26, 2022 Filed Jun 1, 2022 00:17 UTC	REPLIGEN CORP RGEN · Entity 486	GrantStock Option (Right to Buy) · Derivative	1,298	$0.00 Strike: $159.17	$0.00	Disclosure SEC source: 0000899243-22-020276 · doc4.xml · derivative · entry 2 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,298 Underlying: Common Stock · 1,298 shares Expires 2032-05-26 F2 · derivative.exercise_date: Award vests in full on the earlier of May 26, 2023, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined. Read SEC document
May 26, 2022 Filed Jun 1, 2022 00:17 UTC	REPLIGEN CORP RGEN · Entity 486	GrantCommon Stock	534	$0.00	$0.00	Disclosure SEC source: 0000899243-22-020276 · doc4.xml · nonDerivative · entry 1 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,896 F1 · shares: Mr. Muir was awarded 534 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 26, 2023, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document
May 26, 2022 Filed May 31, 2022 20:28 UTC	Neuronetics, Inc. STIM · Entity 6248	GrantCommon Stock	38,910	Not disclosed	Not disclosed	Disclosure SEC source: 0001062993-22-013869 · form4.xml · nonDerivative · entry 1 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,271 F1 · shares: Represents a restricted stock unit ("RSU") award that vests on the earlier of (a) May 26, 2023, and (b) the Company's next annual meeting of stockholders, in each case subject to continuous service of the Reporting Person through such date. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F3 · balance_after: Reflects an adjustment to total holdings to exclude 12 RSUs inadvertently included in prior reports. Read SEC document
June 17, 2021 Filed Jun 21, 2021 20:05 UTC	G1 Therapeutics, Inc. GTHX · Entity 87413	GrantStock Options (Right to Buy) · Derivative	19,620	$0.00 Strike: $21.97	$0.00	Disclosure SEC source: 0001562180-21-004394 · primarydocument.xml · derivative · entry 2 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,620 Underlying: Common Stock · 19,620 shares Expires 2031-06-17 F4 · derivative.exercise_date: The shares underlying this option will vest in their entirety twelve months after June 17, 2021, subject to the Reporting Person's continued service as a director. Read SEC document
June 17, 2021 Filed Jun 21, 2021 20:05 UTC	G1 Therapeutics, Inc. GTHX · Entity 87413	GrantCommon Stock	4,389	$0.00	$0.00	Disclosure SEC source: 0001562180-21-004394 · primarydocument.xml · nonDerivative · entry 1 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,358 F1 · shares: Represents a restricted stock unit ("RSU") award that vests in its entirety twelve months after June 17, 2021, subject to the Reporting Person's continued service as a director. F2 · price: Each RSU represents a contingent right to receive one share of Issuer common stock F3 · balance_after: Represents 170,969 shares of common stock and 4,389 restricted stock units Read SEC document
May 27, 2021 Filed Jun 1, 2021 22:28 UTC	Neuronetics, Inc. STIM · Entity 6248	GrantCommon Stock	7,137	Not disclosed	Not disclosed	Disclosure SEC source: 0001062993-21-005245 · form4.xml · nonDerivative · entry 1 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,373 F1 · shares: Represents a restricted stock unit ("RSU") award that vests on the earlier of (a) May 27, 2022, and (b) the Company's next annual meeting of stockholders, in each case subject to continuous service of the Reporting Person through such date. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document
May 13, 2021 Filed May 18, 2021 01:57 UTC	REPLIGEN CORP RGEN · Entity 486	GrantStock Option (Right to Buy) · Derivative	1,151	$0.00 Strike: $169.65	$0.00	Disclosure SEC source: 0000899243-21-019712 · doc4.xml · derivative · entry 2 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,151 Underlying: Common Stock · 1,151 shares Expires 2031-05-13 F2 · derivative.exercise_date: Award vests in full on the earlier of May 13, 2022, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.